Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females aged \>/= 18 years
Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucinous or clear cell tumors) or Adenocarcinoma of the prostate
At least 1 unidimensional measurable lesion (suitable for RECIST evaluation) or for patients without measurable disease, CA 125 levels \>/= 2 times the upper limit of normal (ULN) within 3 months and confirmed within 2 weeks prior to first infusion (ovarian cancer) or PSA value \>/= 5 ng/mL (HRPC).
Progression of disease (HRPC) despite adequate androgen-inhibiting hormone therapy.
Progression of disease (Ovarian Cancer) or symptomatic relapse after previous therapy (elevated CA125 levels alone are insufficient for inclusion) WHO performance status 0 to 1
No clinical residual neuropathy (CTCAE Grade 0 at baseline)
Adequate recovery from previous surgery, radiation, and chemotherapy (excluding alopecia)
Adequate function of major organs and systems.
Survival expectation =3 months
Histologically or cytologically proven:
1. Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucionous cell tumors or clear cell tumors that have a clear cell component of \>33%)
Any concomitant malignancy: the following exceptions are allowed: Non-melanoma skin cancer, Carcinoma in situ of the cervix, Malignancy with definitive treatment \>/= 5 years ago without relapse.
Diabetes mellitus (even if controlled only by special diet)
History of chronic hepatitis B or C, or known HIV infection
Seizure disorder requiring medication (such as steroids or anti-epileptics)
Inability to swallow oral medications
Prior treatment with epothilones
Concomitant use of neurotoxic drugs
Concomitant use of compounds that have potentially positive effects towards symptoms of neuropathy
